VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis

Jordan W. Conway; Jorja Braden; Serigne Lo; Richard A Scolyer; Matteo S. Carlino; Alexander M. Menzies; Georgina V. Long; Inês Pires da Silva

doi:10.3390/cancers15205012

Related publications

Report2023

A meta-analysis of VEGF inhibitor efficacy in patients with liver metastases across cancer types.

Jordan W. Conway, Jorja Braden, Serigne Lo, Richard A Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Inês Pires da Silva

Article2022

VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review.

Ines Esteves Domingues Pires Da Silva, Serigne Lo, Jordan W. Conway, Richard A Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

Article2006

Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis

Davide Mauri, Nicholas Pavlidis, Nikolaos P. Polyzos, John P A Ioannidis

Article2020

Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value

Raymond L. Barnhill, Pieter‐Jan van Dam, Peter Vermeulen, Gabriel Champenois, Nicolás André, Robert V. Rawson, James S. Wilmott, John F. Thompson, Georgina V. Long, Nathalie Cassoux, Sergio Román-Román, Klaus J. Busam, Richard A Scolyer, Claire Lugassy

Article2021

Comparison of liver cancer incidence and survival by subtypes across seven high‐income countries

Mark J. Rutherford, Melina Arnold, Aude Bardot, Jacques Ferlay, Prithwish De, Hannah Tervonen, Alana Little, Oliver Bucher, Nathalie Jacques, Anna Gavin, Gerda Engholm, Bjørn Møller, Dianne O’Connell, Neil D. Merrett, Donald Maxwell Parkin, Freddie Ian Bray, Isabelle Soerjomataram